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are equipments or iSTAT for Glucose, BUN, Bilirubin, lactate and
lood gas analysis. Disposable Digital oxymeters can be used for
arly detection of hypoxia at affordable price.
Another milestone is the recent evidence of Artesunate as supe-
iod toquinine for better survival rate (AQUAMATandSEAQUAMAT
tudy)
Use of blood transfusion has not yet been studied conclusively,
ut recent reports indicate that Erythropheresis has a promising
ossibility. Use of albumin has not been established. Bolus ﬂuid
herapy was shown to be deleterious.
Weconducteda studyonuseof anti-oedemameasure (mannitol
n cerebralmalaria) and the results strongly contraindicated its use.
Similarly caution should be taken in using Enteral therapy in
omatose patients and frequent use of Central venous catheters.
The mortality can be inﬂuenced by early Renal replacement
herapy. Use of recent biomarkers to detect Acute Kidney Injury
arly for intervention may hold the key in coming years. (viz. NGAL
tc)
ttp://dx.doi.org/10.1016/j.ijid.2012.05.110
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ovel resources to fund health enterprises and develop new
rugs
. Waldvogel
Director, Executive Board, WKD, Geneva, Switzerland
Development of novel drug entities and their adequate dis-
ribution to patients in diverse social and geographical settings
re amongst the formidable challenges to science, industry, gov-
rnmental agencies and health organizations. Both processes are
xtremely complex, characterized by many hurdles and poor
fﬁciency, due to lack of human motivation of administrative col-
aboration and of ﬁnancial resources. This presentation will focus
rimarily on a better distribution and usage of the presently avail-
ble ﬁnancial resources.
Drug development is a process which ﬂows from preclinical
esearch (target identiﬁcation, toxicity, pharmakokinetics) tophase
-3 clinical testing (dose ﬁnding, proof of concept and pivotal tri-
ls), and ﬁnally to acceptance by the regulatory authorities. From
0’000 initial compounds, only 10 will lead to clinical trials and
bout 2 will eventually reach the market. The costs of such a pro-
ess are considerable, in the range of 800 M US$ in out-of-pocket
xpenses and require new modes of risk mitigation. Between 2006
nd 2010, 10 large corporate and 10 large traditional venture funds
ave led this enterprise, totalling more than 700 deals, within a
ulti billion US$ European and US market. The investment strat-
gy, results and perspectives of one of the top funds, the Novartis
enture Funds, will be presented and discussed.
At the other end of the pipeline, novel or standard products have
o reach the communities whether afﬂuent or in ﬁnancial need.
heir distribution and the organization of adequate health policies
or the poor in developing countries represent another, still largely
nmet world challenge. It entails helping those with no or low
ncome to have access to loans and to appropriate ﬁnancial services
nd from there to adequate health care systems The microﬁnance
ovement, created in 1970 by Yunus in Bangladesh and which hasnfectious Diseases 16S (2012) e2–e157
expanded rapidly worldwide, is one of the promising ﬁnancia and
economic strategies tomeet this goal. There are presently 25 billion
US$ at work in the microﬁnance movement, for an estimated 250
billion US$ potential. Principles, boundaries criticisms and outlook
of this new ﬁnancial system will be presented, taking Symbiotics
Inc. – one of the large institutions providing such services – as an
example.
Adequate utilization of the presently available resources –
whether by ﬁnancing innovation or providing acceptable services
to the poor - should allow with time a better access of everyone to
human health needs.
http://dx.doi.org/10.1016/j.ijid.2012.05.111
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Clinical research in the context of rapidly emerging public
health threats
J. Farrar
Centre For Tropical Diseases, Ho Chi Minh City, Viet Nam
A key lesson from a series of recent outbreaks of emerging
pathogens of global public health importance including SARS-CoV,
highly pathogenic avian inﬂuenza A (H5N1) virus, Nipah virus and
the 2009H1N1 virus pandemicwas thatmounting clinical research
in response to a rapidly emerging infectious disease is extremely
challenging and often delayed. During these events, important
pathogenesis and clinicalmanagementdata camemostly fromsites
that were already undertaking related clinical studies including
those on inter-pandemic inﬂuenza (e.g., SEAICRN, Institute Pas-
teur Networks, Chinese University of Hong Kong, and University
of Hong Kong) or from established national or regional research
networks such as the Canadian and Australia/New Zealand Criti-
cal Care Trials Group. However there was very little cross-border
coordination, unlike that which now exists in epidemiology and to
an extent in virology and genomics. The clinical research response
was cumbersome and slow despite years of global preparations
for a potentially devastating inﬂuenza pandemic of avian origin
or the next SARS-like outbreak. Although observational registries
were mobilized, initiatives to launch randomized controlled trials
or more sophisticated biologic studies generally missed the ini-
tial waves of the 2009 H1N1 pandemic and in many cases failed
to enrol sufﬁcient numbers of patients across the entire clinical
spectrum of disease into studies, even during subsequent waves.
During the 2009 H1N1 virus pandemic the efforts to prepare for
a respiratory disease outbreak allowed a reasonably rapid and
coordinated response on epidemiologic and diagnostic aspects of
disease but failed in the timely conduct of clinical research aimed
at improving patient management or understanding pathogenesis.
The failure to have coordinated, comparable data on clinical man-
agement and pathogenesis of 2009 H1N1 virus infection meant
that we missed the opportunity to improve patient outcomes.
Indeed this has been a problem in almost all epidemics over the
last decade (Nipah, SARS, H5N1, and in outbreaks of VHF) with
very little research aimed at improving clinical management or
understanding pathogenesis. This has demonstrated that unless
something is done now to change the barriers faced in 2009, the
next inﬂuenza (or other) outbreak will result in a similar missed
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pportunity to save lives. Furthermore, no integrated analyses exist
f combined microbiological/virological, immunological, clinical,
pidemiological, and genetic data for comprehensive assessment
f host-emerging pathogen interactions that can inform preven-
ion and control activities, and guide clinical management. There
s an urgent need to establish a sustainable consortium of clin-
cal research groups with broad geographic coverage (including
ow resource settings), cross-border coordination, commitment to
pen access, and capacity to conduct complementary high-quality,
ospital-based pathogenesis and clinical management studies and
he ﬂexibility to respond immediately to rapidly emergent threats.
e need a new paradigm for clinical research in the context of
apidly emerging public health threats and one appropriate to the
orts of challenges we will face in the 21st Century.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.112
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nfectious diseases surveillance and alert systems
. Madoff
ProMED-mail, Boston, MA, USA
Prompt detection of infectious disease outbreaks is required
o ensure timely responses that reduce morbidity and mortality,
nd mitigate social and economic disruption. Traditional public
ealth surveillance systems rely on hierarchical structures where
roviders, laboratories and healthcare institutions report deﬁned
iseases to local authorities. Local authorities in turn report to
egional authorities that report to national ofﬁcials, who then
eport to international bodies such as WHO. While this system
as many strengths, it is expensive and has critical weaknesses as
ell e.g., slow reporting, inevitable breaks in the chain of commu-
ication, disincentives to report, and failure to report undeﬁned
r unrecognized illnesses. The past twenty years has seen enor-
ous innovation in nontraditional public health reporting systems.
roMED was perhaps the ﬁrst system to exploit the Internet to
llow nontraditional sources of health information such as media,
rsthand clinician and lay observer reports to be widely dissemi-
ated and serve as early warnings of outbreaks, thus encouraging
ransparency in detection and reporting of emerging disease and
ther biohazardous threats. It has enhanced reporting in under-
erved areas through the development of regional programs such
s PRO/MBDS in Southeast Asia. The growing “ﬁrehose” of data
hat can be mined for public health purposes has led to a num-
er of novel strategies for harnessing this information. GPHIN and
ealthMap utilize web crawling, coupled with human data cura-
ion, to rapidly reportdiseaseevents.Otherbiosurveillance systems
nclude Medisys and BioCaster. Deidentiﬁed search engine queries
rom Google and Yahoo, the so-called “searchstream,” have been
sed to monitor community levels of inﬂuenza and dengue. The
ontents of Twitter messages and other social media content can
egeolocated,monitored, analyzed, and interpreted to showtrends
n outbreaks and public sentiment regarding vaccination and other
ublic health interventions. Cell phone usage patterns can detect
nusual events such as disease outbreaks and can track patterns
f movements and migration. Cell phones themselves, now nearly
biquitous, have become tools for rapid reporting of health events.nfectious Diseases 16S (2012) e2–e157 e45
The revised International Health Regulations, enacted in 2005 and
adopted in 2007 have codiﬁed the use of informal information
sources and promote the rapid and transparent ﬂow of public
health data.
http://dx.doi.org/10.1016/j.ijid.2012.05.113
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Delivering HIV treatment & care in resource limited settings -
Therapeutic mobile units
F.-X. Mbopi-Keou1,∗, G.C.M. Kalla2, F. Djoukoué3, L. Dempouo
Djomassi4, B. Sagnia3, F. Angwafo III 1, V. Colizzi5, L.Montagnier3,
S. Mboup6, L. Bélec7
1 Ministry of Health & University of Yaounde I, Yaounde, Cameroon
2 University Teaching Hospital, Yaounde, Cameroon
3 Chantal Biya Foundation, Yaounde, Cameroon
4 Ministry of Health, Yaounde, Cameroon
5 University of Rome “Tor Vergata”, Rome, Italy
6 Université Cheikh Anta Diop, Dakar, Dakar, Senegal
7 University Rene DEscartes & Georges Pompidou University Hospital,
Paris, France
A weak state health infrastructure and a disparate system of
rural clinics render thedeliveringof treatment and care ofHIV/AIDS
patients in sub-Saharan Africa extremely difﬁcult. Furthermore,
because patients living in remote areas do not have access to lab
facilities, we developed a decentralized strategy based on bringing
the needed services closer to the people, through the use of Ther-
apeutic Mobile Units (TMU) as potentially useful means to follow
up adults and children undergoing antiretroviral treatment.
Using the TMU of the National Public Health Laboratory of the
CameroonMinistry ofHealth,we conducted several cross-sectional
surveys on epidemiological, biological and clinical features of
HIV/AIDS in young and elderly patients in Cameroon. The screening
of HIV-speciﬁc antibodies was carried out using rapid tests. Inde-
terminate or positive samples were immediately retested. People
diagnosed as HIV-infected were provided free biological monitor-
ing and referred to health care centres. The TMU was also equipped
with the Auto40 cytometer for CD4 determination. A FACSCalibur
cytometer was used as reference method.
From April 2005 to July 2011, 120 campaigns were organised
in Cameroon (average of 277 volunteers tested per day). Out of
32, 970 volunteers who received a pre-test counselling, 32, 869
(20,937 males; 11,932 females) tested for HIV (acceptance rate of
99.69%). Their average age was 31 years. Amongst those, 32,569
(99.08%) received post-test counselling. The overall HIV prevalence
was 6.06% [with higher rates in women, data not shown]. CD4 test-
ing was performed using the Auto40 cytometer and gave a perfect
correlation with the reference method (FASCSCalibur) [mean±SD
CD4 T cell count was 1041±317 cells/ml by Auto40, and 1032±294
cells/ml by FACSCalibur; r2=0.982]. For patients receiving ART, our
medical staff provided support in monitoring treatment, recording
information about patient’s medical status, resolving the barriers
to drug adherence and others factors that may affect a patient ART
therapy (data not shown).
